| Labcorp

<span>In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products</span>

October 8, 2023

In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products

Coresta SSPT 2023 -- This study was a proof of concept suggesting that MucilAir™ tissues can be used to differentiate between combustible cigarettes or HTP and ENDS products with regards to cytotoxicity assessment. These tissues are also useful in elucidating pathways of cytotoxicity.

<span>In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products</span>

October 8, 2023

In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products

Coresta SSPT 2023 -- Assays for the detection of chromosome damage in mammalian cells cultured in vitro are recommended in regulatory guidelines as a complement to Ames tests in a genotoxicity test battery. An alternative to measuring structural aberrations in mitotic cells is to measure micronuclei.

<span>Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability</span>

October 8, 2023

Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability

Coresta SSPT 2023 -- The present study aimed to validate the performance of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing three different test articles: cigarettes, electronic nicotine delivery systems (ENDS) and electronic tobacco heated products (eHTPs).

October 9, 2023

Labcorp Molecular Bioanalytical Services Brochure

Count on Labcorp Molecular Bioanalytical Services breadth and depth of scientific expertise to help you along your drug development journey. From cell to gene therapies and biotech to pharma clients, our highly experienced subject matter experts will partner with you to deftly advance your drug development goals along the development continuum.

October 19, 2023

Seamless end-to-end logistical coordination in CAR T-cell therapies: on time, tracked and secure

The chimeric antigen receptor (CAR) T-cell journey includes three distinct phases: collecting the patient's white blood cells through apheresis, modifying the patient's T-cells to manufacture the CAR T-cells, and, finally, infusing the new fighter T-cells into the patient.

October 19, 2023

Coordinating global capabilities to support a gene therapy targeting a rare neurodegenerative disorder

An emerging biotech company was searching for an experienced partner to help their early-phase efforts to advance a gene therapy that targeted a rare neurodegenerative disease.

October 22, 2023

Clinicopathological characterizations of post-surgical vascular access button (VAB) sequelae in rats

National AALAS 2023 -- The surgical implantation of intra-vascular catheters for chronic direct vascular access has produced an essential animal model in rodent preclinical research. Historically, rat catheterization systems included an external port secured via a thoracic harness.

October 25, 2023

End-to-end support to advance gene therapies for rare retinal diseases

As a promising therapeutic candidate targeting rare inherited retinal diseases was spun out of an academic medical center, an emerging biotech needed a knowledgeable and agile partner to provide analytical testing of their product and ensure the project followed an expedited timeline.

October 28, 2023

Pathologic findings in post-surgical vascular access button (VAB) complications in rats

ACVP 2023 -- The introduction of vascular access button (VAB) devices has increased the availability and efficiency of long-term direct vascular access for preclinical research in multiple species. Life-limiting complications from their implantation and usage is rarely reported in the literature.

November 1, 2023

BioPharma Solutions - Expedite Your Drug Development Program

Where are you in your drug development journey? Find out how to expedite your drug development program.

管理您的健康

疾病与治疗领域

治疗模式与方法

科学实验室学科

实验室

行业

In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products

In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products

Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability

Labcorp Molecular Bioanalytical Services Brochure

Seamless end-to-end logistical coordination in CAR T-cell therapies: on time, tracked and secure

Coordinating global capabilities to support a gene therapy targeting a rare neurodegenerative disorder

Clinicopathological characterizations of post-surgical vascular access button (VAB) sequelae in rats

End-to-end support to advance gene therapies for rare retinal diseases

Pathologic findings in post-surgical vascular access button (VAB) complications in rats

BioPharma Solutions - Expedite Your Drug Development Program